Can we get antibiotics right for kids on ECMO?
NCT ID NCT06426836
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how antibiotics behave in the bodies of critically ill newborns, infants, and children who are on a heart-lung machine called ECMO. Researchers want to find out if current doses are high enough to fight infections without causing harm. The goal is to improve dosing guidelines for these vulnerable patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2016
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Up to 15 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients admitted to the pediatric intensive care unit or cardiac intensive care unit * patient age : 1,8 kg-15 years * patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin) * intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred) * extracorporeal membrane oxygenation circuit Exclusion Criteria: * no catheter in place for blood sampling * absence of parental/patient consent * known hypersensitivity to beta-lactam antibiotics and ciprofloxacin
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amikacin are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Queen Fabiola Children's University Hospital
RECRUITINGBrussels, Brussels Capital, 1020, Belgium
-
Universitair hospital
RECRUITINGLeuven, 3000, Belgium
-
University Hospital
RECRUITINGGhent, 9000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a dosing calculator hit the target for sick Kids' antibiotics?
- How do HIV drugs behave when kidneys fail? study measures blood levels
- Can a copy of a cancer antibody match the original in the body?
- Can a new Omega-3 molecule bypass fat digestion?
- Can a natural antibody quiet inflammation? a new trial investigates
- Can a simple calcium tablet help prevent postpartum bleeding?